In This Section      
 

Search Results

Title:
S1802 Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Protocol Number:
NCTNS1802
Phase:
Phase II
Physician:
Michael Gorin
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
The purpose of this study is to compare the effects, good and/or bad, of adding either prostate removal surgery or radiation therapy to standard systemic therapy (SST) that is used to treat prostate cancer.
Eligibility:
Gentleman with prostate cancer that has spread and are either beginning hormone therapy for the first time or have been on hormone therapy for less than 28 weeks may be eligible to participate.
Treatment:
If you decide to take part in this study, you will receive either only standard systemic therapy (SST) or you will get SST and either surgery to remove your prostate or radiation therapy. The choice of radiation or surgery is up to you and your doctor. For all patients, you will get treatment until your disease gets worse. After you finish your study treatment, your doctor will continue to follow your condition for up to 8 years. Your doctor will watch you for side effects and to see how your cancer affects you. You will have clinic visits every three months for the first three years, then every six months until your prostate cancer becomes worse. After it worsens, you will have clinic visits every six months for the first three years and then once a year thereafter.
Population:
Adult
Last Update
03/05/2019 05:03 AM